• English
  • Deutsch
  • Log In
    or
  • Research Outputs
  • Projects
  • Researchers
  • Institutes
  • Statistics
Repository logo
Fraunhofer-Gesellschaft
  1. Home
  2. Fraunhofer-Gesellschaft
  3. Artikel
  4. Primary and secondary resistance to tyrosine kinase inhibitors in lung cancer
 
  • Details
  • Full
Options
2014
  • Zeitschriftenaufsatz

Titel

Primary and secondary resistance to tyrosine kinase inhibitors in lung cancer

Abstract
Background: Tyrosine kinase inhibitors (TKI) have emerged as important therapeutic agents for the treatment of several types of cancer including lung cancer. Recent research attempts show that only a small population of cancer patients responds to TKI and furthermore, these patients eventually develop resistance. Studies support the classification of resistance in primary and secondary resistance. Materials and Methods: In the present study the differentiation between primary and secondary resistance to TKI in lung cancer cell lines was investigated. Lung cancer cell lines were tested for viability, apoptosis and cell cycle after exposure to the TKI erlotinib and gefitinib. Results: Cells with primary resistance showed similar cell-cycle patterns to those with secondary resistance but differences were observed between the two groups in the viability and apoptosis assays. Conclusion: Understanding the effects of TKI on cell signaling pathways would shed light on the mechanisms of acquired resistance and the differences between primary and secondary resistance.
Author(s)
Simasi, Jacinta
Fraunhofer-Institut für Zelltherapie und Immunologie IZI
Schubert, Andreas
Fraunhofer-Institut für Zelltherapie und Immunologie IZI
Oelkrug, Christopher
Fraunhofer-Institut für Zelltherapie und Immunologie IZI
Gillissen, Adrian
Klinik für Lungen- und Bronchialmedizin-Klinikum Kassel
Nieber, Karen
Universität Leipzig
Zeitschrift
Anticancer research
Thumbnail Image
Language
Englisch
google-scholar
IZI
Tags
  • lung cancer

  • apoptosis

  • cell cycle

  • resistance

  • tyrosine kinase inhib...

  • Cookie settings
  • Imprint
  • Privacy policy
  • Api
  • Send Feedback
© 2022